1 min to read News Posted on February 8, 2023 Takeda Completes Acquisition of Nimbus Therapeutics' TYK2 Program Subsidiary – Marketscreener.com Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary Marketscreener.com Source: Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary – Marketscreener.com share tweet share Report: SPACs and De-SPACing: Considerations for Going Public Through a Combination with a SPACSPAC Promoters Lost $1B+ in 2022, and There’s More Pain to Come – 24/7 Wall St.Why Buy a SPAC Before It Identifies a Target?S&P 500 2023 Outlook: Stay Alive In The First Half – Seeking Alpha Tags: SPACs